NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

BeOne Medicines AG (ONC) Stock Analysis

BeOne Medicines AG (ONC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ONC

$386.46

+$1.96 (+0.51%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ONC with… →

ONC Key Statistics

As of Oct 21, 2026
Trading
Open
$383.86
Previous Close
$384.50
Day's Range
382.62–388.66
52-Week Range
253.95–388.66
Volume
548.93K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.61
Valuation
Market Cap
$43.97B
P/E Ratio
69.13
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
37.00
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.81
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.17
EPS (ttm)Profit attributable to each share over the last twelve months.
5.59
Financials (FY)
Revenue (FY)
$5.34B+40.23%
Net Income (FY)
$286.93M
Profit marginThe share of revenue left as profit after all costs and taxes.
10.70%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
104.92M
1-Year Return
+22.40%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
383.95K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ONC closed at $386.46, +22.40% over 1 year.

BeOne Medicines AG (ONC) has a market capitalization of $43.97B.

In fiscal 2025, ONC reported revenue of $5.34B.

ONC Stock Return by Calendar Year

BeOne Medicines AG (ONC) 10-year return: what $10,000 became

1 year
$10,000 $12,240
+22.40%
5 years
$10,000 $10,298
+2.98%
10 years
$10,000 $116,650
+1,066.50%

If you had invested $10,000 in BeOne Medicines AG (ONC) 10 years ago, at the close on October 21, 2016, it would have been worth $116,650 at the close on October 21, 2026: +1,066.50% in total, +27.85% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+27.20%
2025+64.48%
2024+2.41%
2023−18.00%
2022−18.82%
2021+4.85%
2020+55.88%
2019+18.18%
2018+43.53%
2017+221.87%
2016 (partial year)+14.39%

As of October 21, 2026.

ONC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$5.34B$286.93M5.4%
2024$3.81B−$644.79M−16.9%
2023$2.46B−$881.71M−35.9%
2022$1.42B−$2.00B−141.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$5.34B$4.67B$447.14M$286.93M5.4%
2024$3.81B$3.22B−$568.20M−$644.79M−16.9%
2023$2.46B$2.08B−$1.21B−$881.71M−35.9%
2022$1.42B$1.13B−$1.79B−$2.00B−141.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ONC Valuation vs Biotechnology Median

Median of 608 stocks
MetricONCBiotechnology medianvs median
P/E69.1316.604.2x the median
P/S ratio7.1713.3046% below
Profit margin10.70%−38.31%49.0 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BeOne Medicines AG (ONC) is capitalised at $43.97B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 12,000.

ONC last closed at $386.46 on October 21, 2026. That is +$1.96 (+0.51%) against the previous close. Over the past 52 weeks the price has ranged from $253.95 to $388.66. The latest close sits 52.18% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $5.34B. Against the prior fiscal year total of $3.81B, that is a change of +40.23%. Net income for the same year was $286.93M. Profit margin runs at 10.7%. That is 49 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to 5.59.

Across the 4 fiscal years on file, revenue moves from $1.42B in 2022 to $5.34B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

ONC trades at a trailing price-to-earnings ratio of 69.13. That is 4.2 times the Biotechnology median of 16.6. On forward earnings the ratio is 37. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.81. Measured against sales, the shares trade at 7.17 times revenue. On price-to-sales that is 46.06% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +22.40%. Measured over 10 years, that is +27.85% a year compounded. Beta against the wider market is reported at 0.61. Annualized volatility over the trailing 10 years is 55.48%.

Growth & Income

No dividend is on file for ONC.

The strongest complete calendar year on file is 2017 at +221.87%; the weakest is 2022 at −18.82%. Of the 9 complete calendar years on file, 7 finished higher. 2026 is still running; the total return is +27.20% year to date.

Peer Comparison

BeOne Medicines AG (ONC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BeOne Medicines AG ONC $43.97B 69.1
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. BeOne Medicines AG trades at a P/E of 69.1.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 RVMD

Revolution Medicines, Inc.

$41.64B

 RPRX

Royalty Pharma plc

$35.91B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Visit website →